The ability to both quantify and localize left ventricular (LV) contractile dysfunction should improve clinical outcomes in several ways by addressing limitations of the current nonquantitative metrics of regional LV function.
Fayetteville, Arkansas (PRWEB) July 21, 2015
CardioWise, Inc. announced today that its Multiparametric Strain Analysis (MPSA) of the heart was used in a clinical research study, “Quantifying ‘Normalized’ Regional Left Ventricular Contractile Function in Ischemic Coronary Artery Disease,” published in the July 2015 issue Journal of Thoracic and Cardiovascular Surgery. The study results were accompanied by an Editorial Commentary, entitled “Quantifying regional left ventricular contractile function: Leave it to the machines?” written by the independent reviewers of the manuscript.
Washington University in St. Louis School of Medicine Professor Dr. Michael K. Pasque and his research team led by Dr. Matthew Henn, Research Fellow completed the research study on 120 patients, 60 normal volunteers and 60 patients with known coronary artery disease (CAD) confirmed by angiography. All patients underwent cardiac MRI with MPSA. Upon blind review, 55% (33/60) of the CAD patients had significant regional contractile abnormalities by one of three “gold standard” criteria 1) Q waves on electrocardiogram (ECG); 2) infarct on radionuclide single positron emission computed tomography (SPECT); or 3) akinesia or dyskinesia on echocardiography (echo). Consistency among all gold standard metrics was found in only 19% (6/31) of CAD patients who had at least two available metrics. Blinded MRI-based MPSA localization of contractile abnormalities was accurate in 89% (ECG), 97% (SPECT), and 95% (echo).
The team of independent reviewers commented: “The ability to both quantify and localize left ventricular (LV) contractile dysfunction should improve clinical outcomes in several ways by addressing limitations of the current nonquantitative metrics of regional LV function. First, this method creates an objective standard that will increase consistency and accuracy across the board by reducing the interuser and intertemporal variability that has plagued echocardiographic interpretation of LV function in the past. Furthermore, the simplicity of interpreting and displaying these results may increase patients’ understanding of their coronary artery disease.” “We commend Henn and his colleagues for developing an intuitive, quantitative method to classify LV contractile function that has the potential to spur significant improvement in clinical decision making relative to the inconsistent, qualitative tests used today.”
What this means to both heart physicians and patients is that MPSA, in conjunction with cardiac MRI, offers a clearer, more accurate interpretation of heart function. As demonstrated in the accompanying image, the CardioWise MPSA interpretation on the bottom is much more detailed than that of the SPECT image above it. The quantitative images that MPSA provides will give both doctors and patients better tools to make decisions about cardiac care.
CardioWise™ is commercializing patented, non-invasive Cardiac Magnetic Resonance Imaging (CMR) analysis software that produces a quantified 4D image model of the human heart, called Multiparametric Strain Analysis™ (MPSA™). CardioWise heart analysis software combined with cardiac MRI is a single diagnostic test that is able to provide quantitative analysis of the myocardium, arteries and valves with an unprecedented level of detail. It has the opportunity to become the new gold standard of care for heart health analysis. CardioWise™ is a VIC Technology Venture Development™ portfolio company.